Premium
Long term response in a patient with neoplastic meningitis secondary to melanoma treated with 131 I‐radiolabeled antichondroitin proteoglycan sulfate Mel‐14 F(ab′) 2
Author(s) -
Cokgor Ilkcan,
Akabani Gamal,
Friedman Henry S.,
Friedman Allan H.,
Zalutsky Michael R.,
Zehngebot Lee M.,
Provenzale James M.,
Guy Cynthia D.,
Wikstrand Carol J.,
Bigner Darell D.
Publication year - 2001
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(20010501)91:9<1809::aid-cncr1200>3.0.co;2-l
Subject(s) - medicine , vomiting , headaches , meningitis , nausea , melanoma , chemotherapy , radiation therapy , hearing loss , cancer , meningeal carcinomatosis , surgery , dermatology , cerebrospinal fluid , cancer research , audiology
Even with novel chemotherapeutic agents and external beam radiation therapy, the prognosis of neoplastic meningitis secondary to malignant melanoma is still dismal. The authors report a case study of a 46‐year‐old white female who presented with progressive hearing loss, severe headaches, nausea, vomiting, and a rapid decline in neurologic status. She was referred to Duke University Medical Center after conventional chemotherapy for malignant melanoma failed. She was enrolled in a Phase I trial of 131 I‐labeled monoclonal antibody Mel‐14 F(ab′) 2 fragment administered intrathecally. Within a year after her treatment, she recovered, having a normal neurologic exam except for residual bilateral hearing loss. The authors discuss dosimetry, preclinical, and clinical studies conducted with Mel‐14 F(ab′) 2 and introduce a potentially promising therapy option in the treatment of neoplastic meningitis in patients with malignant melanoma. Currently, the patient remains neurologically normal except for a mild bilateral hearing loss more than 4 years after treatment and has no radiographic evidence of neoplastic meningitis. Cancer 2001;91:1809–13. © 2001 American Cancer Society.